The non-opioid pain treatment is intended to reduce pain, improve recovery time and enhance the overall patient experience during and after surgery, according to a Feb. 11 news release.
The FDA-cleared system temporarily blocks pain signals by targeting specific nerves with cold therapy, according to the release. It is performed before surgery to reduce the need for opioids during the recovery process.
Patients who undergo joint replacements with an Iovera treatment report improved mobility, faster return to daily activities and reduced reliance on pain medications, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
